Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Glaukos ( (GKOS) ) has provided an update.
On February 20, 2025, Glaukos Corporation announced their financial results for the fourth quarter and full year of 2024. The company reported record net sales of $105.5 million for Q4 2024, marking a 28% increase year-over-year, and a total of $383.5 million for the full year, a 22% increase. Despite a net loss in both the quarter and year, the company reduced its operating losses compared to 2023. Glaukos also introduced a 2025 revenue guidance of $475 million to $485 million, indicating continued strong business momentum.
More about Glaukos
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and began commercial activities for iDose® TR, a long-duration glaucoma drug therapy, in 2024. Glaukos also offers the only FDA-approved corneal cross-linking therapy for keratoconus.
YTD Price Performance: 7.28%
Average Trading Volume: 566,246
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.43B
For detailed information about GKOS stock, go to TipRanks’ Stock Analysis page.
